Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study

• Published in: PloS one 2017-10, Vol.12 (10), p.e0186018
• Main Authors: Risselada, Marije, Linder, Keith E, Griffith, Emily, Roberts, Brittney V, Davidson, Gigi, Zamboni, William C, Messenger, Kristen M
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Animal tissues; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - toxicity; Area Under Curve; Biocompatibility; Biology and Life Sciences; Bone cancer; Cancer therapies; Carboplatin; Carboplatin - administration & dosage; Carboplatin - pharmacokinetics; Carboplatin - toxicity; Care and treatment; Chemotherapy; Complications; Complications and side effects; Dosage and administration; Female; In vivo methods and tests; Inductively coupled plasma mass spectrometry; Injections, Subcutaneous; Medicine and Health Sciences; Muscles; Pharmacokinetics; Pharmacology; Pharmacy; Physical Sciences; Pilot Projects; Platinum; Poloxamer - administration & dosage; Rats; Rats, Sprague-Dawley; Skin; Studies; Toxicity; Tumors; Veterinary colleges; Veterinary medicine; Wound healing
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0186018

The objectives of this study were to assess the pharmacokinetics and safety of subcutaneously delivered carboplatin in poloxamer 407 in rats. Carboplatin (5mg/rat) in 0.5ml poloxamer 407 (1.0 ml total volume) was administered subcutaneously in a right subcutaneous perineal incision in all 12 treatment rats. Three control rats received 1.0 ml of poloxamer 407. Total platinum was measured in plasma q24hrs from 0 to 168hrs. Protein-unbound platinum was measured in plasma at 168hrs. After sacrifice on day 7, total platinum was determined in wound bed muscle. Platinum concentrations in all samples were measured by ICP-MS. Wounds were visually assessed daily for 7 days. Perineal tissues (full wound bed including muscle, subcutis, skin) were assessed histologically and scored. Total platinum was detectable in plasma from 24 to 168 hrs. Total plasma platinum AUC and Cmax were 9,165.3 ng/mL•h and 129.4 ng/mL. Day 7 total platinum concentration in muscle was approximately 10-fold higher than total plasma platinum concentration. No unbound platinum was detected in plasma samples at 168 hours. No wound healing complications were detected at any time point, nor was tissue necrosis observed histologically. The results of this study suggest that subcutaneous carboplatin in poloxamer 407 can be used in vivo providing direct tissue exposure to carboplatin without significant local effects or systemic absorption and without wound healing complications.